Vera Gesheva1, Stela Chausheva1, Nadia Stefanova1, Nikolina Mihaylova1, Lyuba Doumanova1, Krassimira Idakieva2, Andrey Tchorbanov3. 1. Laboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. 26, 1113 Sofia, Bulgaria. 2. Institute of Organic Chemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., bl. 9, 1113 Sofia, Bulgaria. 3. Laboratory of Experimental Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. 26, 1113 Sofia, Bulgaria. Electronic address: tchorban@microbio.bas.bg.
Abstract
BACKGROUND: New generated subunit vaccines are characterized by increased safety and lack of side effects, however they suffer from weak immunogenicity. The adjuvants are substances that have the ability to enhance the magnitude and duration of the immune response and to increase vaccine efficacy, but the different vaccines may require diverse adjuvants. The urgent need of novel adjuvant formulations occurs, thus ensuring protective cellular and humoral responses against infectious pathogens. The hemocyanins, oxygen binding copper proteins in the hemolymph of molluscs and arthropods, are widely used as peptide carriers and vaccine adjuvants. RESULTS: In the present study we promote the hemocyanin isolated from the terrestrial gastropod Helix pomatia (HPH) as bio-adjuvant, combined with standard antigens. The purified HPH combined with influenza virus hemagglutinin intersubunit peptide (IP) or with tetanus toxoid (TT) were used for immunization. Administration of tetanus toxoid combined with HPH in mice resulted in an increased number of anti-TT IgG producing plasmocytes and induced a significant increase of B and T cell proliferation. The level of the anti-TT IgG antibodies in mice sera was comparable to the group administered with TT+Al(OH)3. An immunization of experimental animals with IP combined with H. pomatia hemocyanin led to generation of strong anti-influenza cytotoxic response. CONCLUSION: The vaccination of mice demonstrates that the HPH is acceptable as a potential bio-adjuvant for subunit vaccines and it could be used as a natural adjuvant or protein carrier.
BACKGROUND: New generated subunit vaccines are characterized by increased safety and lack of side effects, however they suffer from weak immunogenicity. The adjuvants are substances that have the ability to enhance the magnitude and duration of the immune response and to increase vaccine efficacy, but the different vaccines may require diverse adjuvants. The urgent need of novel adjuvant formulations occurs, thus ensuring protective cellular and humoral responses against infectious pathogens. The hemocyanins, oxygen binding copper proteins in the hemolymph of molluscs and arthropods, are widely used as peptide carriers and vaccine adjuvants. RESULTS: In the present study we promote the hemocyanin isolated from the terrestrial gastropod Helix pomatia (HPH) as bio-adjuvant, combined with standard antigens. The purified HPH combined with influenza virus hemagglutinin intersubunit peptide (IP) or with tetanus toxoid (TT) were used for immunization. Administration of tetanus toxoid combined with HPH in mice resulted in an increased number of anti-TT IgG producing plasmocytes and induced a significant increase of B and T cell proliferation. The level of the anti-TT IgG antibodies in mice sera was comparable to the group administered with TT+Al(OH)3. An immunization of experimental animals with IP combined with H. pomatia hemocyanin led to generation of strong anti-influenza cytotoxic response. CONCLUSION: The vaccination of mice demonstrates that the HPH is acceptable as a potential bio-adjuvant for subunit vaccines and it could be used as a natural adjuvant or protein carrier.
Authors: Juan José Mora Román; Miguel Del Campo; Javiera Villar; Francesca Paolini; Gianfranca Curzio; Aldo Venuti; Lilian Jara; Jorge Ferreira; Paola Murgas; Alvaro Lladser; Augusto Manubens; María Inés Becker Journal: J Immunol Res Date: 2019-01-20 Impact factor: 4.818
Authors: Diego A Díaz-Dinamarca; Michelle L Salazar; Byron N Castillo; Augusto Manubens; Abel E Vasquez; Fabián Salazar; María Inés Becker Journal: Pharmaceutics Date: 2022-08-11 Impact factor: 6.525